Enhancer RNAs profiling in colorectal cancer liver metastases reveals novel molecular subtypes with prognostic and therapeutic relevance.

ABSTRACT:

Background

Enhancer RNAs (eRNAs) are essential for cancer initiation and progression. However, the landscape of eRNAs and the clinical significance of eRNAs in colorectal cancer (CRC) liver metastases (CRLM) remain largely unknown.

Methods

We comprehensively profiled eRNAs in a CRLM cohort and delineated eRNA-based CRLM subtypes through unsupervised clustering of eRNAs and validated the subtyping framework in an external cohort. Molecular characteristics, immune infiltration, prognostic outcomes, and chemotherapy responses of the novel CRLM subtypes were further explored. Finally, we explored chemoresistance-related eRNAs and tentatively investigated the roles of eRNAs in CRC oxaliplatin resistance in vitro.

Results

Three novel eRNA-based CRLM subtypes, known as C1, C

SUBMITTER: Bu X 

PROVIDER: S-EPMC12158866 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature